BRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical...
Collaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market By capitalizing on the long half-life of tumor targeting...
The Baranzate site (Italy) is the first Dipharma manufacturing facility to receive Anvisa certificationMILAN, Italy, Dec. 01, 2022 (GLOBE NEWSWIRE)...
ELOX common stock expected to begin trading on a split-adjusted basis on December 2, 2022WATERTOWN, Mass., Dec. 01, 2022 (GLOBE...
GFH009 exhibits robust activity against small cell lung cancer xenografts, both as monotherapy and in combination with PARP inhibitor olaparib...
SAN MATEO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics announced today that it received approval from the New...
CINCINNATI, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today...
First patient dosed in Phase 1b study of CTX-471 in combination with KEYTRUDA® in cancers of the lung, head and...
Raised $25 million from a Series C financing Proceeds to advance development of first-in-class oncology pipeline across multiple indications DUBLIN,...
Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics to participate in a live moderated panel discussion on Thursday,...
LOWELL, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences...
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the...
WALTHAM, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical...
60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing Sarcoma First-Relapse Patients No Disease...
Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like...
ZUG, Switzerland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating...
Funding supports advancement of samuraciclib, an oral CDK7 inhibitor, in combination with endocrine therapy for HR+, HER2- advanced breast cancer...
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
In-person event and live webcast to follow oral presentation of data from KOMET-001 at ASH in New OrleansSAN DIEGO, Dec....
